Joo Hee Lee1, Ga Yeon Lee2, Seok Jin Kim2, Ki Hyun Kim2, Eun-Seok Jeon2, Kyung-Han Lee1, Byung-Tae Kim1, Joon Young Choi1. 1. Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, 135-710 Seoul Republic of Korea. 2. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Abstract
PURPOSE: Although several case reports and case series have described (18)F-FDG PET/CT in amyloidosis, the value of (18)F-FDG PET/CT for diagnosing amyloidosis has not been clarified. We investigated the imaging findings of (18)F-FDG PET/CT in patients with primary systemic AL amyloidosis. METHODS: Subjects were 15 patients (M:F = 12:3; age, 61.5 ± 7.4 years) with histologically confirmed primary systemic AL amyloidosis who underwent pretreatment (18)F-FDG PET/CT to rule out the possibility of malignancy or for initial workup of alleged cancer. For involved organs, visual and semiquantitative analyses were performed on (18)F-FDG PET/CT images. In total, 22 organs (10 hearts, 5 kidneys, 2 stomachs, 2 colons, 1 ileum, 1 pancreas, and 1 liver) were histologically confirmed to have primary systemic AL amyloidosis. RESULTS: F-FDG uptake was significantly increased in 15 of the 22 organs (68.2 %; 10 hearts, 2 kidneys, 1 colon, 1 ileum, and 1 liver; SUVmax = 7.0 ± 3.2, range 2.1-14.1). However, in 11 of 15 PET-positive organs (78.6 %; 10 hearts and the ileum), it was difficult to differentiate pathological uptake from physiological uptake. Definitely abnormal (18)F-FDG uptake was found in only 4 of the 22 organs (18.2 %; 2 kidneys, 1 colon, and the liver). (18)F-FDG uptake was negative for pancreas and gastric lesions. CONCLUSIONS: Although (18)F-FDG PET/CT showed high uptake in two-thirds of the organs involving primary systemic AL amyloidosis, its sensitivity appeared to be low to make differentiation of pathological uptake from physiological uptake. However, due to the small number of cases, further study for the role of (18)F-FDG PET/CT in amyloidosis will be warranted.
PURPOSE: Although several case reports and case series have described (18)F-FDG PET/CT in amyloidosis, the value of (18)F-FDG PET/CT for diagnosing amyloidosis has not been clarified. We investigated the imaging findings of (18)F-FDG PET/CT in patients with primary systemic AL amyloidosis. METHODS: Subjects were 15 patients (M:F = 12:3; age, 61.5 ± 7.4 years) with histologically confirmed primary systemic AL amyloidosis who underwent pretreatment (18)F-FDG PET/CT to rule out the possibility of malignancy or for initial workup of alleged cancer. For involved organs, visual and semiquantitative analyses were performed on (18)F-FDG PET/CT images. In total, 22 organs (10 hearts, 5 kidneys, 2 stomachs, 2 colons, 1 ileum, 1 pancreas, and 1 liver) were histologically confirmed to have primary systemic AL amyloidosis. RESULTS:F-FDG uptake was significantly increased in 15 of the 22 organs (68.2 %; 10 hearts, 2 kidneys, 1 colon, 1 ileum, and 1 liver; SUVmax = 7.0 ± 3.2, range 2.1-14.1). However, in 11 of 15 PET-positive organs (78.6 %; 10 hearts and the ileum), it was difficult to differentiate pathological uptake from physiological uptake. Definitely abnormal (18)F-FDG uptake was found in only 4 of the 22 organs (18.2 %; 2 kidneys, 1 colon, and the liver). (18)F-FDG uptake was negative for pancreas and gastric lesions. CONCLUSIONS: Although (18)F-FDG PET/CT showed high uptake in two-thirds of the organs involving primary systemic AL amyloidosis, its sensitivity appeared to be low to make differentiation of pathological uptake from physiological uptake. However, due to the small number of cases, further study for the role of (18)F-FDG PET/CT in amyloidosis will be warranted.
Authors: F Javier de Haro-del Moral; Alicia Sánchez-Lajusticia; Manuel Gómez-Bueno; Pablo García-Pavía; Clara Salas-Antón; Javier Segovia-Cubero Journal: Rev Esp Cardiol (Engl Ed) Date: 2012-03-30
Authors: David P Dutka; Michael Pitt; Domenico Pagano; Marco Mongillo; David Gathercole; Robert S Bonser; Paolo G Camici Journal: J Am Coll Cardiol Date: 2006-12-05 Impact factor: 24.094
Authors: Hyunjong Lee; Ji Hyun Kim; Yeon-Koo Kang; Jae Hoon Moon; Young So; Won Woo Lee Journal: Medicine (Baltimore) Date: 2016-07 Impact factor: 1.889
Authors: Weijia Li; Dipan Uppal; Yu-Chiang Wang; Xiaobo Xu; Damianos G Kokkinidis; Mark I Travin; James M Tauras Journal: Diagnostics (Basel) Date: 2021-05-30
Authors: Riemer H J A Slart; Andor W J M Glaudemans; Olivier Gheysens; Mark Lubberink; Tanja Kero; Marc R Dweck; Gilbert Habib; Oliver Gaemperli; Antti Saraste; Alessia Gimelli; Panagiotis Georgoulias; Hein J Verberne; Jan Bucerius; Christoph Rischpler; Fabien Hyafil; Paola A Erba Journal: Eur Heart J Cardiovasc Imaging Date: 2020-12-01 Impact factor: 6.875
Authors: Riemer H J A Slart; Andor W J M Glaudemans; Olivier Gheysens; Mark Lubberink; Tanja Kero; Marc R Dweck; Gilbert Habib; Oliver Gaemperli; Antti Saraste; Alessia Gimelli; Panagiotis Georgoulias; Hein J Verberne; Jan Bucerius; Christoph Rischpler; Fabien Hyafil; Paola A Erba Journal: Eur J Nucl Med Mol Imaging Date: 2020-10-27 Impact factor: 9.236